April 27, 2018 - 9:00am

Health and Human Services Commission John H. Winters Human Services Complex Public Hearing Room
701 W. 51st St.
Austin, TX 78751

Add to My Calendar

Webcasting Available

This meeting will be webcast. To access the webcast, go to https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings  the day and time of the meeting.

  1. Call to order
  2. Approval of minutes from January 26, 2018 (vote required)
  3. Elect vice-chair (vote required)
  4. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the January 26, 2018, meeting
  5. New business:
    Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL):
    1. Anti-allergens, oral
    2. Antibiotics, inhaled
    3. Anticoagulants
    4. Antidepressants, other
    5. Antidepressants, SSRIs
    6. Antidepressants, tricyclic
    7. Antihyperuricemics
    8. Antiparkinson agents
    9. Anxiolytics
    10. Beta-blockers
    11. Bile salts
    12. BPH treatments
    13. Bronchodilators, beta agonist
    14. COPD agents
    15. Cough and cold agents
    16. Erythropoiesis stimulating proteins
    17. Glucocorticoids, inhaled
    18. HAE treatments
    19. Hypoglycemics, SGLT2
    20. Immune globulins
    21. Immunomodulators, atopic dermatitis
    22. Lincosamides/oxazolidinones/streptogramins
    23. Lipotropics, other
    24. Lipotropics, statins
    25. PAH agents, oral and inhaled
    26. Pancreatic enzymes
    27. Sedative hypnotics
    28. Urea cycle disorders, oral
      Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
    1. Admelog Solostar Pen / Hypoglycemics, insulin and related agents
    2. Admelog Vial / Hypoglycemics, insulin and related agents
    3. Adzenys ER Suspension /Stimulants and related agents
    4. Bydureon Bcise / Hypoglycemics, incretin mimetics/enhancers 
    5. Enbrel Cartridge / Cytokine and CAM antagonists 
    6. Lyrica CR / Neuropathic pain 
    7. Ozempic / Hypoglycemics, incretin mimetics/enhancers
    8. Qtern / Hypoglycemics, incretin mimetics/enhancers
    9. Retin-A Micro 0.06% Pump /Acne agents
    10. Solosec / Antibiotics, GI
    11. Vyzulta / Ophthalmics, glaucoma agents
    12. Ximino / Tetracyclines
  6. Executive work session
    Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
  7. Lunch
  8. Announcements of drugs recommended for the Medicaid PDL (vote required)
  9. Retrospective DUR:  Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR intervention:
      1. Asthma disease management
      2. Bipolar disorder management
      3. Migraine prevention and treatment
      4. Psychotropic drugs in adults
    2. Report on recent retrospective DUR intervention outcomes:
      1.  Diabetes disease management 2017
      2. Naloxone for opioid-related overdose
    3. Retrospective DUR proposals:  (vote required)
      1. Diabetes disease management
      2. Proton pump inhibitors
      3. Rheumatoid arthritis disease management
  10. Prospective prior authorization proposals (clinical edits):  Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Anxiolytics and Sedatives/Hypnotics - Buspirone criteria revision
    2. Cystic Fibrosis Agents - addition of Symdeko (Tezacaftor/Ivacaftor and Ivacaftor)
  11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Anticoagulants - oral, direct-acting (DOACs)
    2. Benzodiazepines - oral/rectal (nonsedative/hypnotic)
    3. Complement Inhibitor and Enzyme/Protein Replacement therapy
    4. HMG-CoA Reductase Inhibitors (Statins)
    5. Low Molecular weight heparins
    6. Nebulized bronchodilators
  12. Adjourn
  13. Next meeting date: July 27, 2018

Contact:  Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public.  No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.